Haleon plc Form 6-K Summary
Business context and reporting period
This Form 6-K, dated July 26, 2022, reports ownership notifications and a director/PDMR shareholding transaction following Haleon plc’s demerger from GSK. It does not contain quarterly or annual operating results. The relevant transaction dates were July 21 and July 25, 2022.
Key financial and ownership metrics
- Issued ordinary share capital used for the ownership calculations: 9,234,573,831 shares.
- GSK plc reported 1,195,320,110 Haleon voting rights, representing 12.94% of total voting rights. The interest was held indirectly through several GSK-related entities and Vidacos Nominees Limited.
- Glaxo Group Limited reported a direct holding of 502,727,073 shares, representing 5.44% of voting rights.
- The GSK group’s aggregate 12.94% interest was unchanged; the filing describes a transfer of GSK plc’s retained 5.44% direct stake to Glaxo Group Limited.
- Haleon CEO Brian McNamara received 235 Haleon American Depositary Shares on July 21, 2022, in respect of personal shares held under the demerger arrangements. The filing reports no price for the transaction.
- The filing provides no revenue, profit, cash flow, margin, debt, liquidity or other operating-performance metrics.
Material changes versus the prior comparable disclosure
GSK plc’s reported aggregate voting position was unchanged at 12.94%. The material change was an internal transfer of 5.44% of Haleon’s shares from direct ownership by GSK plc to indirect ownership through Glaxo Group Limited. Glaxo Group Limited reported the 5.44% position as a new holding.
Guidance, outlook, risks and unusual items
The filing contains no management guidance, business outlook, risk-factor update, contingencies or operating commentary. The reported items are ownership restructuring within the GSK group and a PDMR share receipt connected with the demerger.
Investor verification checklist
- Verify the GSK group’s aggregate 12.94% voting interest and the allocation between the 5.44%, 4.74%, 1.78% and 0.98% ownership chains.
- Confirm that the 5.44% transfer to Glaxo Group Limited did not change GSK’s aggregate economic or voting interest.
- Review Haleon’s prospectus and subsequent filings for restrictions, sell-down plans or other arrangements relating to GSK’s retained stake.
- Confirm the terms and treatment of the 235 ADSs received by the CEO under the demerger arrangements.
- Use separate financial filings to assess Haleon’s revenue, profitability, cash generation, leverage and liquidity, as those figures are not provided here.